| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
AKTS
Aktis Oncology, Inc.
|
Jun 16, 2026 | BUY |
Strong Buy
+31.0% avg upside
8 analysts
|
$40.00
65.95% Upside
|
· |
|
NUVL
Nuvalent
|
Jun 09, 2026 | HOLD |
Buy
-0.3% avg upside
21 analysts
|
— | +0.1% |
|
BMRN
BioMarin Pharmaceutical
|
May 22, 2026 | BUY |
Strong Buy
+72.7% avg upside
52 analysts
|
— | +1.7% |
|
CLYM
Climb Bio
|
May 19, 2026 | BUY |
Strong Buy
+57.9% avg upside
18 analysts
|
— | · |
|
ALMS
Alumis Inc.
|
Mar 27, 2026 | BUY |
Strong Buy
+63.6% avg upside
11 analysts
|
$46.00
96.45% Upside
|
-3.7% |
|
BHVN
Biohaven Ltd.
|
Mar 09, 2026 | BUY |
Strong Buy
+87.5% avg upside
25 analysts
|
— | +32.9% |
|
TYRA
Tyra Bioscience
|
Feb 23, 2026 | BUY |
Strong Buy
+57.9% avg upside
17 analysts
|
$55.00
94.26% Upside
|
-12.7% |
|
REGN
Regeneron
|
Jan 30, 2026 | BUY |
Strong Buy
+26.9% avg upside
57 analysts
|
$870.00
42.73% Upside
|
-17.8% |
|
COGT
Cogent Biosciences
|
Jan 26, 2026 | BUY |
Strong Buy
+7.4% avg upside
26 analysts
|
$60.00
73.71% Upside
|
-9.6% |
|
LXEO
Lexeo Therapeutics, Inc.
|
Jan 13, 2026 | BUY |
Strong Buy
+313.4% avg upside
11 analysts
|
$25.00
407.02% Upside
|
-31.5% |
|
ARDX
Ardelyx
|
Jan 08, 2026 | BUY |
Strong Buy
+124.7% avg upside
21 analysts
|
$19.00
214.01% Upside
|
-20.9% |
|
AARD
Aardvark Therapeutics, Inc.
|
Dec 02, 2025 | BUY |
Buy
+386.3% avg upside
12 analysts
|
$47.00
1095.94% Upside
|
-48.5% |
|
TSHA
Taysha Gene Therapies
|
Nov 25, 2025 | BUY |
Strong Buy
+103.3% avg upside
21 analysts
|
$13.00
102.44% Upside
|
+34.9% |
|
MNPR
Monopar Therapeutics Inc
|
Nov 14, 2025 | BUY |
Strong Buy
+46.7% avg upside
18 analysts
|
$123.00
82.32% Upside
|
-24.0% |
|
MGTX
Meiragtx Holdings
|
Oct 20, 2025 | BUY |
Strong Buy
+130.8% avg upside
13 analysts
|
$29.00
156.17% Upside
|
+16.4% |
|
AMGN
Amgen
|
Oct 10, 2025 | HOLD |
Buy
-11.6% avg upside
57 analysts
|
— | +22.5% |
|
KLRS
Kalaris Therapeutics
|
Sep 16, 2025 | BUY |
Buy
+170.8% avg upside
13 analysts
|
$23.00
387.26% Upside
|
-2.2% |
|
VRTX
Vertex Pharmaceuticals
|
Sep 02, 2025 | HOLD |
Strong Buy
-2.7% avg upside
61 analysts
|
$401.00
11.14% Downside
|
+14.5% |
|
ACRS
Aclaris Therapeutics
|
Feb 18, 2025 | BUY |
Strong Buy
+122.9% avg upside
15 analysts
|
$13.00
188.94% Upside
|
+37.8% |
|
RARE
Ultragenyx Pharmaceutical
|
Feb 14, 2025 | BUY |
Strong Buy
+142.0% avg upside
36 analysts
|
$140.00
410.21% Upside
|
-51.7% |
|
QTTB
Q32 Bio
|
Feb 11, 2025 | HOLD |
Buy
+345.2% avg upside
24 analysts
|
$4.00
66.37% Downside
|
+22.2% |
|
ABVX
Abivax SA Sponsored ADR
|
Feb 10, 2025 | BUY |
Strong Buy
+20.7% avg upside
15 analysts
|
$42.00
57.65% Downside
|
+1697.6% |
|
KPTI
Karyopharm Therapeutics
|
Jan 27, 2025 | BUY |
Strong Buy
+146.1% avg upside
18 analysts
|
$75.00
731.44% Upside
|
-31.5% |
|
ABBV
AbbVie
|
Jan 27, 2025 | BUY |
Buy
+2.8% avg upside
43 analysts
|
$227.00
4.79% Upside
|
+30.8% |
|
BIIB
Biogen
|
Oct 30, 2024 | BUY |
Strong Buy
+25.1% avg upside
51 analysts
|
$315.00
60.20% Upside
|
-17.4% |
|
AGIO
Agios Pharma
|
Oct 23, 2024 | BUY |
Strong Buy
+73.8% avg upside
29 analysts
|
$56.00
63.91% Upside
|
-5.1% |
|
BCRX
BioCryst
|
Oct 23, 2024 | BUY |
Strong Buy
+103.2% avg upside
24 analysts
|
$20.00
122.45% Upside
|
-10.8% |
|
IOBTQ
IO Biotech
|
Sep 16, 2024 | BUY |
Buy
+78483.3% avg upside
6 analysts
|
$10.00
166566.70% Upside
|
· |
|
ALXO
ALX Oncology Holdings
|
Aug 09, 2024 | BUY |
Strong Buy
+1086.5% avg upside
11 analysts
|
$8.00
422.84% Upside
|
-74.1% |
|
IONS
Ionis Pharmaceuticals
|
Oct 25, 2023 | BUY |
Strong Buy
+13.3% avg upside
43 analysts
|
$58.00
21.66% Downside
|
-11.7% |
|
ARGX
Argenx Se
|
Oct 25, 2023 | BUY |
Strong Buy
-15.8% avg upside
46 analysts
|
$600.00
31.56% Downside
|
+18.0% |
|
AKBA
Akebia Therapeutics
|
Oct 25, 2023 | BUY |
Strong Buy
+831.9% avg upside
16 analysts
|
$4.00
273.80% Upside
|
+98.8% |
|
TVTX
Travere Therapeutics
|
Jul 24, 2023 | HOLD |
Strong Buy
-15.9% avg upside
22 analysts
|
$22.00
60.19% Downside
|
-37.0% |
|
CDXS
Codexis
|
Apr 25, 2023 | BUY |
Strong Buy
+291.5% avg upside
13 analysts
|
$14.00
444.84% Upside
|
-34.9% |
|
CALC
CalciMedica
|
Nov 22, 2022 | HOLD |
Buy
+3672.8% avg upside
9 analysts
|
$28.00
3606.62% Upside
|
-45.9% |
|
ONON
On Holding AG
|
Jul 25, 2022 | BUY |
Strong Buy
+29.5% avg upside
33 analysts
|
$28.00
28.00% Downside
|
+81.3% |
|
GYRE
Gyre Therapeutics
|
May 23, 2022 | BUY |
Strong Buy
+212.0% avg upside
15 analysts
|
$3.00
52.00% Downside
|
+11.3% |
|
SLDB
Solid Biosciences
|
May 18, 2022 | HOLD |
Strong Buy
+92.3% avg upside
23 analysts
|
$30.00
260.24% Upside
|
-26.3% |
|
INO
Inovio Pharmaceuticals
|
May 11, 2021 | HOLD |
Buy
+808.5% avg upside
19 analysts
|
$6.00
438.16% Upside
|
-72.1% |
|
RIGL
Rigel
|
Apr 13, 2021 | BUY |
Strong Buy
-27.5% avg upside
17 analysts
|
$8.00
75.62% Downside
|
-14.4% |
|
RMTI
Rockwell Med
|
Mar 27, 2020 | BUY |
Buy
+1445.2% avg upside
11 analysts
|
— | -46.1% |
|
TEVA
Teva Pharmaceutical
|
Apr 18, 2019 | HOLD |
Buy
-6.8% avg upside
39 analysts
|
— | -28.5% |
|
TARA
Protara Therapeutics
|
Aug 07, 2017 | HOLD |
Strong Buy
+1153.9% avg upside
21 analysts
|
— | +66.7% |
|
AFFY
Affymax
|
Mar 19, 2013 | HOLD |
Hold
+942207.7% avg upside
3 analysts
|
— | -17.9% |
|
CERS
Cerus
|
Feb 29, 2012 | BUY |
Strong Buy
+99.1% avg upside
10 analysts
|
$6.00
122.27% Upside
|
-12.5% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.